Gonadal and Adrenal Abnormalities in Drug Users: Cause or Consequence of Drug Use Behavior and Poor Health Outcomes

Todd T. Brown, Amy B. Wisniewski and Adrian S. Dobs
Division of Endocrinology and Metabolism, Johns Hopkins University, Baltimore, MD

Abstract: Opiates and cocaine both have effects on adrenal and gonadal function. Opiates suppress the hypothalamic-pituitary adrenal (HPA) axis, whereas cocaine leads to HPA activation. Opiates also cause gonadal dysfunction in both men and women. During withdrawal from opiates and cocaine, the HPA axis is activated which may reinforce relapse behavior. This review describes these hormonal effects and explores the potential consequences, including the effects on mood cognition and cardiovascular risk. Modification of the drug-induced hormonal dysfunction may represent a treatment strategy for drug rehabilitation.

Key words: Gonadal and adrenal abnormalities, drug users, poor health outcomes, cardiovascular risk

INTRODUCTION

Opiates and cocaine are considered to be the main problem drugs of abuse worldwide[1]. In the United States, 2.3 million are current cocaine users and an estimated 119,000 abuse heroin according to a recent national survey[2]. Abuse of both of these drugs is associated with multiple poor health outcomes, reduced quality of life and criminal behavior.

Opiates and cocaine both have important physiologic effects on multiple organ systems. In the endocrine system, both of these drugs can have immediate and potentially long-term effects on the hypothalamic-pituitary-adrenal (HPA) and the hypothalamic-pituitary-gonadal (HPG) axes. The consequences of these changes are unclear. By affecting mood, stress, cognition and energy, these drugs may lead to or potentiate depressive symptomatology and reduced quality of life. In addition, changes in gonadal and adrenal function may induce changes in body composition, which could increase cardiovascular risk. During drug withdrawal, some studies have shown activation of the HPA axis, possibly contributing to relapse behavior.

This review will focus on the extent to which the HPG and HPA axes are altered with exposure to opiates and cocaine and the potential for these changes to lead to depression, reduced quality of life and illness. Given the high prevalence of HIV infection in drug users, possible interactions between drugs of abuse, HIV infection and antiretroviral treatment will also be considered. Drug abusers are a vulnerable population. To optimize drug abuse treatment, a full understanding of the physiologic, psychological and social issues is required. The endocrine abnormalities present in drug users may be a potential target for drug abuse treatment and prevention.

Gonadal abnormalities in drug use: Normal gonadal function requires intact communication between the hypothalamus, the pituitary and the testes in males and the ovaries in females. Gonadotropin releasing hormone (GnRH) is secreted in a pulsatile fashion from the preoptic area and the medial basal region of the hypothalamus, inducing secretion of leutinizing hormone (LH) and follicle stimulating hormone (FSH) from the anterior pituitary. In males, LH stimulates testosterone synthesis in the Leydig cells of the testes and FSH induces spermatogenesis in Sertoli cells. In females, FSH causes maturation of an ovarian follicle and LH induces ovulation.

GnRH secretion is partially regulated by endogenous opioids, such as β-endorphins, which produce tonic inhibition of its release[3]. Exogenously administered opioids also inhibit GnRH secretion, resulting in HPG dysfunction at the level of the hypothalamus. In experimental models, methadone administration was found to significantly reduce testosterone concentrations by over two-thirds of the baseline values after 60 minutes, mediated in part by the inhibition of dopaminergic activity in the hypothalamus[4]. In addition to their effects on the hypothalamus, opioids have also been shown to directly reduce testosterone synthesis[5].

Opiate-induced effects on HPG axis integrity can lead to clinical hypogonadism. In a study of detoxified heroin addicts, intravenous administration of heroin (10 mg) produced acute suppression of LH secretion, leading to reduced testosterone concentration with a peak effect after 4-6 hours[6]. In accord with these experimental findings, multiple cross-sectional studies in heroin dependent subjects have demonstrated decreased gonadotropin and testosterone levels[7,11], which can be reversed with the administration of opiate antagonists[12]. This latter observation suggests a direct
Adrenal dysfunction in drug use: In healthy individuals, pulsatile secretion of corticotropin releasing hormone (CRH) in the hypothalamus causes pituitary secretion of adrenocorticotropic hormone (ACTH), which stimulates cortisol synthesis and release from the adrenal cortex. Opiate administration disrupts this pathway through the inhibition of CRH release, leading to reduced cortisol production. Inconsistent with this observation, small studies have shown a high prevalence of adrenal insufficiency in opioid dependent subjects, with a high prevalence of abnormal ACTH stimulation tests. In addition, administration of metyrapone, a cortisol synthesis inhibitor used to test the integrity of the HPA axis, shows decreased HPA activation in heroin dependent subjects, with a high prevalence of abnormal ACTH stimulation tests in abstinent patients. The extent to which depressive symptoms in drug users are related to abnormalities in the HPG or HPA axes has not been clarified.

Major depression and psychological stress cause activation of the HPA axis. With the high prevalence of depression and anxiety symptoms among drug users, psychological dysfunction may be another mechanism by which the HPA axis is activated in drug users. The consequences of this activation have not been fully explored, but these abnormalities may further contribute to metabolic alterations, leading to increased cardiovascular disease risk.

The cognitive consequences of drug abuse, as well as the cognitive impact of the associated risks such as HIV infection and endocrine pathologies that are observed with drug abuse, constitute an area that requires further study. Depression-related abnormalities in cortisol production are also correlated with memory dysfunction in individuals without HIV infection who are not administering opiates or stimulants. Additionally, there is a large literature concerning the modulatory effects of sex steroid hormones on cognition in people who are neither HIV-infected nor drug users. In vitro human neuronal cultures that include neurotoxic HIV proteins and exposed to a variety of stimulants such as cocaine were protected from the neurotoxic effects of the drugs by treatment with estrogen. Data are currently lacking regarding the potential impact of adrenal and gonadal hormone abnormalities and treatments on cognitive performance in drug abusing populations who may or may not be infected with HIV.

Metabolic complications: In addition to the important effects on mood, gonadal and adrenal dysfunction has
repercussions on metabolism. Low testosterone concentrations cause reduced bone mineral density and alter body composition, leading to decreased lean body mass and increased fat mass. This latter effect, particularly when the fat accumulation is in the central compartment, is strongly related to insulin resistance and increased risk of cardiovascular disease[35]. Hypogonadism has also been associated with increased arterial stiffness, which may further contribute to cardiovascular risk[36].

Abnormal HPA dynamics in the drug user may also lead to metabolic alterations associated with increased cardiovascular risk. Hypercortisolemia, which is observed with cocaine administration and after the acute effects of opiates on the HPA axis have subsided, could also contribute to central adiposity and insulin resistance. In non-drug using populations, HPA axis activation is related to abdominal obesity and insulin resistance in both men and women[6,37]. Whether HPA and HPG dysregulation is involved in the development of cardiovascular risk factors in drug users is unknown.

HIV infection and treatment as a confounder: In the US, over 50% of new HIV infections occur in drug users. Direct viral effects or effects for antiretroviral medications result in a high prevalence of hypogonadism, altered concentrations of sex hormone binding globulins, altered circadian production of steroids, adrenal dysfunction and metabolic abnormalities in HIV infected men and women[38]. For this reason, the relationship between endocrine and metabolic abnormalities in drug users may be confounded by HIV infection and treatment. Alternatively, HIV-infection/treatment could act as an effect modifier, enhancing the impact of opiates and cocaine on endocrine and metabolic parameters in drug users. For this reason, epidemiological studies of endocrinology and metabolism in drug users should include a careful characterization of HIV status and treatment history, such that the effects of drugs of abuse and the effects of HIV and its treatment can be distinguished.

Adrenal and gonadal abnormalities in drug treatment: The hypothalamic-pituitary-adrenal axis also plays a critical role in craving and relapse. In animal models of addiction, experimental manipulation of the HPA axis can alter drug seeking behavior. When CRH is infused into rats previously exposed to heroin, drug-seeking behavior will be reinstated, particularly following physical stress. Conversely, blocking the effects of CRH, using a specific antagonist, attenuates a stress-induced relapse in the same model[39]. In a rat model of cocaine addiction, CRH also plays a synergistic role in stress-induced cocaine seeking behavior[40]. The mechanism underlying these observations is unclear, but glucocorticoids appear to sensitize the mesolimbic system, such that the dopaminergic reward pathway is hyperstimulated upon re-exposure to the drug[41]. Taken together, these experimental findings would suggest that HPA axis activation in cocaine and heroin abusers may lead to relapse behavior.

Indeed, gonadal and adrenal abnormalities are also seen in humans who discontinue opiate and cocaine administration. HPA axis dynamics in drug users shift when opiates are withdrawn. Without the suppressive effect of opiates on the HPA axis, the axis becomes hyperstimulated, resulting in hypercortisolism. This effect can be present 16 days after last opiate consumption[42] and has been attributed to increased release of CRH. Similarly, acute administration of cocaine activates the HPA axis, resulting in hypercortisolism[24,43]. In addition, HPA activation has been observed after cocaine cessation[23] and has been implicated in the pathophysiology of craving.

In human studies, HPA activation during drug use and between drug use episodes also reinforces craving and drug seeking-behavior. Methadone treated patients show withdrawal symptoms when exposed to metyrapone[44]. One interpretation of these data is that the resulting increases in CRH and ACTH after metyrapone may induce these negative effects, which then motivates the subject to seek drugs to alleviate these symptoms. Indeed, CRH has been shown to be important in the anxiogenic and adverse effects of drug withdrawal. In an animal model of opiate dependence, administration of a CRH antagonist reversed the conditioned aversion response elicited by an opiate antagonist[45].

Depression induced by hypogonadism may further lead to HPA activation and contribute to drug-seeking behavior. In addition, hypogonadism may contribute to craving by a more direct mechanism. Low levels of estrogen and testosterone reduce endogenous central nervous system opioid expression[46,47]. The resulting decreases in endogenous opioid levels during withdrawal and abstinence may be associated with craving for opioids and contribute to relapse.

Hormonal treatment of drug abuse: Given the potential role of HPA and HPG axis abnormalities in craving and relapse in drug dependent subjects, these endocrine systems may provide a target to improve drug treatment. In a rat model of cocaine addiction, pre-treatment with the cortisol synthesis inhibitor, ketoconazole, leads to a reduction in cocaine-seeking behavior, accompanied by lower plasma corticosteroid concentrations[48]. In humans, however, a randomized, placebo-controlled trial of ketoconazole in methadone maintained patients failed to show any benefit on illicit drug use behavior. In this trial of 39 subjects, those randomized to 600-900 mg/day of ketoconazole plus evening hydrocortisone (20 mg) were more likely to show evidence of cocaine self-administration compared to the placebo treated group. In contrast to prior animal
studies, ketoconazole failed to suppress plasma cortisol concentrations. The reasons for these unexpected findings are unclear. It was postulated by the authors that patients randomized to ketoconazole may have been self-medicating to minimize the adverse effects of the study drug, including dyspepsia, nausea and body aches. In addition, the use of evening hydrocortisone may have affected the results by further altering HPA axis dynamics. Nevertheless, these results corroborate the findings of a lack of effect with acute administration of ketoconazole\(^{[49]}\). While ketoconazole does not appear to show promise as a potential drug treatment strategy, it is unknown whether other pharmacologic manipulation of the HPA axis will show any efficacy.

The HPG axis is another potential target for the treatment of drug abuse. In experimental animal models, hypogonadal rodents given androgen replacement were less sensitized to the behavioral effects of cocaine\(^{[50,51]}\). However, another animal model showed no effect of testosterone replacement on cocaine self-administration\(^{[52]}\). It is not clear whether the testosterone replacement in hypogonadal drug users will reduce craving and treatment failures.

![Diagram](https://via.placeholder.com/150)

**Fig. 1:** Conceptual Framework of the Hormonal Consequences of Drug Use. Cocaine and intermittent opiate exposure activate the hypothalamic-pituitary-adrenal (HPA) axis. Depression, which may be induced by opiate-related hypogondasim, also contributes to HPA activation. Changes in HPA dynamics lead to cravings and relapse behavior

**CONCLUSION**

The relationship between illicit drug use, abnormalities in gonadal and adrenal function and stress and depression is complex. Adrenal and gonadal dysfunction is both a cause and consequence of drug use behavior (see Fig. 1). There is, however, significant variation in the effect of opiates and cocaine on adrenal and gonadal function with both administration and withdrawal. Further, attempts to manipulate endocrine function in the treatment of addiction have had mixed results. It is possible that certain subsets of drug users are particularly vulnerable to the effects of opiates and cocaine on the HPG and HPA axes. Polymorphisms in the mu-opioid receptor, for example, have been associated with reduced HPA activation in the setting of receptor blockade with naltrexone (Wand, 2002). Whether this genetic variation accounts for differences in the endocrine effects of drug administration and changes in endocrine function during withdrawal requires further study.

The changes in gonadal and adrenal function induced by opiates and cocaine use may have effects on quality of life, mood and cardiovascular risk. Furthermore, alterations in these hormonal axes may be important in the perpetuation of drug use behavior and may serve as targets for improved drug treatment.

**REFERENCES**


